Wockhardt Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Net profit of Wockhardt rose 321.43% to Rs 59.00 crore in the quarter ended December 2025 as against Rs 14.00 crore during the previous quarter ended December 2024. Sales rose 23.16% to Rs 888.00 crore in the quarter ended December 2025 as against Rs 721.00 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Wockhardt will hold a meeting of the Board of Directors of the Company on 10 February 2026.

Powered by Capital Market - Live News

Wockhardt announced that its novel intravenous antibiotic Foviscu? (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis caused by Gram-negative bacteria, including extended-spectrum ?-lactamase (ESBL) producing pathogens. ESBL enzymes make many commonly used antibiotics ineffective and are a major cause of difficult-to-treat hospital infections.

With this milestone, Foviscu? becomes the fifth proprietary antibiotic from Wockhardt to complete a registration-enabling Phase 3 study, following Emrok?, Emrok O?, Miqnaf?, and Zaynich?, further strengthening Wockhardt's leadership in antibiotic discovery space.

In a randomized, double-blind Phase 3 study, Foviscu? was directly compared with meropenem, a ?last-line? gold-standard carbapenem widely used for severe drug-resistant Gram-negative infections. At the Test-of Cure visit, Foviscu? achieved a high clinical cure rate of 93.23% versus 92.31% with meropenem, thereby meeting the primary endpoint and demonstrating therapeutic equivalence with a similarly well-tolerated safety profile. This is the first Phase 3 head-to-head trial of an antibiotic specifically developed for ESBL infections compared with meropenem.

ICMR data show a high burden of ESBLs and rising resistance to commonly used antibiotics such as piperacillin/tazobactam and cefoperazone/sulbactam, increasingly forcing clinicians to rely on carbapenems (meropenem) and thereby accelerating carbapenem resistance. By providing an effective alternative, Foviscu? has the potential to reduce carbapenem use and strengthen antibiotic stewardship to curb antimicrobial resistance. Currently, approximately 65 lakh treatment courses of meropenem, piperacillin/tazobactam, and cefoperazone/sulbactam are used annually in India.

Foviscu? underwent a combined Phase 2 and Phase 3 program which enrolled 323 hospitalized cUTI and AP patients (Phase 2: 60; Phase 3: 263). The most common causative pathogens were Escherichia coli, Klebsiella spp., Enterobacter spp., and Pseudomonas spp. More than half of the Enterobacterales isolates (51.4%) were ESBL-positive, and 33.8% of Gram negatives were resistant to cefepime, underscoring the urgent need for stronger first-line treatment options in India, where ESBL prevalence is high.

Powered by Capital Market - Live News

Wockhardt Ltd is up for a third straight session today. The stock is quoting at Rs 1513.7, up 3.27% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 26081.2. The Sensex is at 84749.13, down 0.37%. Wockhardt Ltd has gained around 15.08% in last one month.

Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has gained around 2.29% in last one month and is currently quoting at 23126.85, up 0.13% on the day. The volume in the stock stood at 6.09 lakh shares today, compared to the daily average of 9.18 lakh shares in last one month.

The PE of the stock is 168.77 based on TTM earnings ending September 25.

Powered by Capital Market - Live News